If you have been reading about pentapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-12. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
==== Encoded combinatorial libraries ==== When dealing with a non-peptide organic libraries library, it is not as simple to determine the identity of the content of a bead as in the case of a peptide one. In order to circumvent this difficulty, methods have been developed to attach molecules that encode the structure of the compound formed in the bead to the beads, in parallel with the synthesis of the library. Ohlmeyer and his colleagues published a binary encoding method. They used mixtures of 18 tagging molecules that, after cleaving them from the beads, could be identified by Electron Capture Gas Chromatography. Sarkar et al. describe chiral oligomers of pentenoic amides (COPAs) that can be used to construct mass encoded OBOC libraries. Kerr et al. introduced an innovative encoding method. An orthogonally protected removable bifunctional linker was attached to the beads. One end of the linker was used to attach the non-natural building blocks of the library, while encoding amino acid triplets were linked to the other end. The building blocks were non-natural amino acids and the series of their encoding amino acid triplets could be determined by Edman degradation. The important aspect of this kind of encoding was the possibility to cleave down from the beads the library members together with their attached encoding tags forming a soluble library. The same approach was used by Nikolajev et al. for encoding with peptides. In 1992, Brenner and Lerner introduced DNA sequences to encode the beads of the solid support that proved to be the most successful encoding method.
== Use during the 20th century == During the 20th century its use declined as governments regulated its ingredients (opium is a controlled substance in many countries). Beginning in late 2011, there was a period in which paregoric was not being manufactured in the United States. As of August 2012, however, the manufacture of paregoric had resumed.
=== Legal status === On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for melphalan. The applicant for this medicinal product is Adienne S.r.l. S.U. Melphalan was approved for medical use in the European Union in November 2020.
Sources: en.wikipedia.org
Loss of NMNAT2 initiates Wallerian degeneration. By contrast, NMNAT2 enhancement opposes the actions of SARM1 which would lead to axon degeneration, but this effect is not due to preventing SARM1 depletion of NAD+. Mice lacking NMNAT2 die before birth, but are completely rescued by SARM1 deletion. Activation of NMNAT2 by Sirtuin 3 (SIRT3) may be a means of inhibiting axon degeneration and dysfunction. The catechin epigallocatechin gallate (EGCG) found in tea can activate NMNAT2 by more than 100%.
Peter V'landys was appointed Chair on 30 October 2019, replacing Peter Beattie who reverted to a commissioner role. Beattie had served as Chair since February 2018. Andrew Abdo served as Interim CEO from late April 2020 until his appointment as CEO in early September 2020.
ISBN 0-921991-50-9. Spaeter, Helmuth (1990). Panzerkorps Grossdeutschland: A Pictorial History. Atglen, Pennsylvania: Schiffer Books. ISBN 0-88740-245-3. Ziemke, Earl F. (2002). Stalingrad to Berlin: The German Defeat in the East. Washington, D.C.: Center of Military History. ISBN 978-1-78039-287-5.
Sources: en.wikipedia.org
From about 1989 to 2018, Ontario has reported a deficit almost every year; the province's net debt increased to approximately $311.6 billion (by October 2018); and Ontario's net debt‐to‐GDP ratio grew from 13.4% to about 40.5% in 2018–19. According to an April 11, 2018 Royal Bank of Canada (RBC) report, which was based on figures provided by the Ford government, the revised estimate of Ontario's deficit was $11.7 billion in 2018–2019 and it was projected to decrease by $1.4 billion in 2019–2020 mainly because of "the removal of the $1 billion contingency reserve." At that time, it was projected that the deficit would be "completely eliminated in 2023–2024 with a small surplus of $0.3 billion." By October 2019, the Financial Accountability Officer, Weltman, said that the FAO had been in error when they—and the Ford government—had projected a $11.7-billion deficit that was reported in the spring 2019 budget. By June 2018, Ontario had "Canada's second-highest public debt per person and a growing budget deficit", according to The Economist. In October 2018, the Ontario Finance Department reported that Ontario's public debt per person, at $23,014, had surpassed that of Quebec at $21,606 in the fiscal year 2017–2018. Newfoundland and Labrador's public debt per capita, at $27,761, was the highest in Canada. By 2019, the Ontario Chamber of Commerce reported that Ontario's debt was over $348 billion—representing about 41% of provincial GDP of almost $850 billion. Ontario's GDP is much larger than any of the other provinces and is almost half of Canada's GDP.
=== Designation process === The NIH funds cancer centers through a P30 Cancer Center Support Grant (CCSG) mechanism. To be eligible to apply, a cancer center must receive at least $10 million in cancer research funding annually. Preparation for these grant applications can be extensive. The most recent grant application prepared by MD Anderson Cancer Center took 24 months to prepare and ran to 2,963 pages. Cancer centers must renew their status with the NIH every 5 years. The NCI considers the certain characteristics essential to a cancer center, and requires that applications address the institutions' resources in the areas of: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, Center Director. Independent or freestanding cancer centers are entities unto themselves and are not considered to be part of a larger institution or university. The center’s administration controls all space, appointments and budgets. These institutions may have university affiliations, but they remain administratively and financially distinct. The NCI also supports Consortium Centers, wherein scientists and clinicians from multiple institutions enter into formal agreements to expand cancer research programs. Importantly, Consortium Partners are not themselves considered NCI-designated. The NCI has strict guidelines on how Consortium Partners can refer to their relationship with their parent Consortium Center.
DNA structure is dominated by the well-known double helix formed by Watson-Crick base-pairing of C with G and A with T. This is known as B-form DNA, and is overwhelmingly the most favorable and common state of DNA; its highly specific and stable base-pairing is the basis of reliable genetic information storage. DNA can sometimes occur as single strands (often needing to be stabilized by single-strand binding proteins) or as A-form or Z-form helices, and occasionally in more complex 3D structures such as the crossover at Holliday junctions during DNA replication.
As expected from in vitro data, sertraline did not alter the human metabolism of the CYP3A4 substrates erythromycin, alprazolam, carbamazepine, clonazepam, and terfenadine; neither did it affect metabolism of the CYP1A2 substrate clozapine. Sertraline did not affect the actions of digoxin and atenolol, which are not metabolized in the liver. Case reports suggest that taking sertraline with phenytoin or zolpidem may induce sertraline metabolism and decrease its efficacy, and that taking sertraline with lamotrigine may increase the blood level of lamotrigine, possibly by inhibition of glucuronidation. CYP2C19 inhibitor esomeprazole increased sertraline concentrations in blood plasma by approximately 40%. Clinical reports indicate that interaction between sertraline and the MAOIs isocarboxazid and tranylcypromine may cause serotonin syndrome. In a placebo-controlled study in which sertraline was co-administered with lithium, 35% of the subjects experienced tremors, while none of those taking placebo did. Grapefruit should be avoided.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.